Emerald Conference 2019 Presentations

Todd-Scattini

Skin in the Game: Why the DoD Should be on the Leading Edge of Cannabis Research

Presenter: Todd Scattini, Global CEO, Harvest 360

John-Abrams

Scientific Director Opening Remarks

Presenter: John Abrams, Ph.D., Chairman & Chief Scientific Officer, Clinical Endocannabinoid System Consortium

Genetic Sleuthing – the power of sequencing for the entire cannabis market

Presenter: Jessica Kristof, M.Sc., VP of Research & Development, Phylos

Over the past decade, chemical analysis for cannabinoid and terpene content has become a widely adopted test. As the final dataset, chemotype results represent the culmination of a long plant development history ending with senescence.

Paul Winkler

Chemovar Cannabis Typing Using Principle Component Analysis on High Resolution Mass Spectral Data

Presenter: Paul Winkler, Food and Beverage Marketing Development Manager

Consumers of Cannabis have long asserted the differences between cultivars, or strains, for user experience. The historical classification scheme of Indica, Sativa, and Hybrid has prevailed as a popular and simplified way to group together Cannabis cultivars of perceived properties and ancestral origin, allowing the consumer to select desired products based on a class-based assumption of its qualities.

John-Abrams

Grammar & Symbols to Translate the Language of Cannabis Chemotypes

Presenter: John Abrams, Ph.D., Chairman and Chief Scientific Officer, Clinical Endocannabinoid System Consortium (CESC) Inc.

Consumers of Cannabis have long asserted the differences between cultivars, or strains, for user experience. The historical classification scheme of Indica, Sativa, and Hybrid has prevailed as a popular and simplified way to group together Cannabis cultivars of perceived properties and ancestral origin, allowing the consumer to select desired products based on a class-based assumption of its qualities.

, MS, Chief Scientific Officer, Technica Botanica

The Role of Genetic Testing in Clinical Outcomes in Cannabinoid and Terpenoid Therapeutics

Presenter: Steve Ottersberg, MS, Chief Scientific Officer, Technica Botanica

This discussion is a result of more than 5 years of clinical and teaching experience in human genetics. When 23 and Me became the first consumer-based genetic testing company, I found a niche in integrating 23 and Me data with clinical lab data to generate precisions medicine treatment plans based upon the patient’s biochemical individuality.

Tarrant_Jeff

A Comparison of Two Cannabis Strains Using EEG and Psychological Measures: Implications for Therapeutic Applications

Presenter: Jeff Tarrant, Ph.D., Director, NeuroMeditation Institute

While cannabis is now widely used for a variety of medicinal and recreational purposes, little is understood about the impact that different cannabis profiles may have. What measurable impact is there on acute changes in brain functioning?

Kalev_Freeman

The American Cannabis Experiment: Extracting Data from the Largest Unregulated Clinical Trial

Presenter: Kalev Freeman, M.D., Ph.D., Consultant, Phyto-Science Institute

While medical marijuana is now legal in most states, few medical schools provide training in cannabis-based medicine. Furthermore, restrictive federal policies and regulations severely limit clinical research on the health effects of cannabis and cannabinoids, limiting the evidence available to physicians.

Linda-Klumpers

Pharmacological Formulation Strategies for Effective Cannabis-based Products

Presenter: Linda Klumpers, Ph.D., Founder & Director, Tomori Pharmacology, Inc.

Hundreds of new cannabis products are launched every year. Despite many of them being aimed at the medical market, few products are created with extensive knowledge of their pharmacology. This includes both how the the active ingredients move through the body, called pharmacokinetics (PK), and what effects the active ingredients have on the body, called pharmacodynamics (PD).

Brad-Douglass

Standardizing the Entourage Effect: Regulating Terpenes & Flavor Additives for Inhalable Cannabis Products without Throwing the Baby Out with the Bathwater

Presenter: Brad Douglass, Ph.D., Vice President of Intellectual Property and Regulatory Affairs, The Werc Shop

Cannabis products cover a wide range of forms that will demand a regulatory scheme that is anchored in existing frameworks for food, dietary supplements, pharmaceuticals, liquor, and tobacco regulation.In this presentation, the importance of establishing ingredient standards for inhalable cannabis products will be addressed.

Matt-Vanden-Eyden

High-Resolution, Comprehensive, and Quantitative Physical Stability Analysis of Cannabis Beverage Emulsions: Homogeneity, Formulation, and Shelf Life

Presenter: Matt Vanden Eynden, Ph.D., Analytical Chemist, Formulaction, Inc.

Cannabis beverage emulsions, just like all other food and beverage products, undergo some sort of stability testing in order to maintain a level of quality that will be passed along to customer. The shelf integrity of these products are also critical over time as oils can break out from their emulsion matrix and produce what is now a heterogeneous product, and therefore unappealing to an end user.

Robert_Martin

Operating a Commercial Cannabis Laboratory in California: A 10 Year Assessment

Presenter: Robert Martin, Ph.D.. CEO, CW Analytical

Yan-Ren-Butcher

Ultraviolet Supplement for Higher Yield, Better Quality and Less Chemical Spray

Presenter: Yan Ren-Butcher, Ph.D., Director of Horticulture Science, Illumitex

This session will review published scientific reports of the effects of UVA and UVB radiations on plant growth and development, quality improvement and disease controls. The possibility of introducing UV spectra to increase THC and other cannabinoids, as well as is becoming widely talked about amongst cannabis growers.

Eric-Kawka

Optimization Study of Supercritical Fluid Extraction of Cannabinoids from Cannabis Sativa

Presenter: Eric Kawka, M.A., Founder, Cattis Scientific

Supercritical fluid extraction (SFE) has been studied and optimized for a variety of purposes in the food and nutraceutical industries. However, optimization data related to the use of SFE for extracting cannabinoids from Cannabis sativa is limited.

Ariel_Bohman
Markus-Roggen

Optimization Study of Supercritical Fluid Extraction of Cannabinoids from Cannabis Sativa

Presenters: Ariel Bohman, Ph.D., Application Scientist, PerkinElmer and Markus Roggen, Ph.D., Founder, Complex Biotech Discovery Ventures

The production of cannabis extracts and oils for both medicinal and recreational products has increased significantly due to greater market demand brought on by legalization and patient demand for a greater diversity of cannabis products. Most cannabis extraction processes undergo a decarboxylation step whereby the carboxylic acid functional group is removed from the cannabinoids converting the naturally occurring acid forms to their more potent neutral forms.

Shawn-Helmueller

Identification of unknown cannabinoid reaction pathways using Ultra-Performance Convergence Chromatography (UPC2) for real-time, high-resolution reaction monitoring

Presenter: Shawn Helmueller, Chief Scientific Officer, Deutsche Process

The medical cannabis industry has seen fantastic growth in both research and industrial scale processing and formulation of new and unique cannabis-based products. As such, new technologies and process optimization strategies are required across each and every stage of the cannabis product development life-cycle.

Sean_Orlowicz

Chromatography and the Art of Method Maintenance

Presenter: Sean Orlowicz, Business Development Manager- Cannabis, Phenomenex

Some say that chromatography is as much of an art as it is a science. While this may be true, what if instead, we think of it as a tool? A specialized tool used to build machines capable of answering questions like, “how safe is this product for consumers?”. The availability of such tools often defines the capabilities of a laboratory.

Marian-Twohig

Routine Analysis of Cannabis for Pesticides and Mycotoxins using UPLC-MS/MS and GC-MS/MS

Presenter: Marian Twohig, Ph.D., Principal Scientist, Waters Corporation

Quantitative methods for residual pesticides and mycotoxins analysis in cannabis should provide reliable coverage and robust methodology for the entire list of analytes to fulfill the state-mandated safety tests. The detection sensitivity and specificity offered by LC/MS/MS is advantageous for determining trace levels of most pesticides and mycotoxins in complex matrices.

Keith-Allen

Genomics of Cannabis Terpene Content Variation

Presenter, Keith Allen Ph.D., Director of Bioinformatics, Steep Hill

Terpenes give cannabis many of its distinctive odors and flavors, and so variation in terpene content is a key factor differentiating strains and will be an important target for breeders. Looking forward to a new wave of craft and medicinal breeding, it is clear that a full understanding of the genetic basis of terpene variation will be an essential starting point.

Toby-Astill

Overcoming the Challenges Associated with Pesticide Analysis of Cannabis and Understanding the Matrix Effects and the Impact of Various Clean-Up Strategies

Presenter: Toby Astill, Ph.D., Sr. Business Manager – Cannabis & Hemp Markets, PerkinElmer

A new analytical LC-MS/MS method has been developed and qualified to allow cannabis laboratories to complete the entire Pesticide assay (including molecules such as Chlordane and pentachloronitrobenzene) in one quick method, using one instrument.

Anthony-Smith

The value of metals testing for risk management and product safety

Presenter: Anthony Smith, Ph.D., Chief Science Officer, EVIO Labs

A number of US States have adopted requirements for heavy metals testing of Cannabis and Cannabis products. There have been lots of murmured presumptions that metals testing will increase costs without doing much to improve harm reduction, the motivation of all public health and safety regulators. We have found that metals testing is driving product safety and supply chain efficiency in the Cannabis industry.

Ken Snoke, President – Emerald Scientific

Thank You & Closing Remarks

Ken Snoke, Chief Executive Officer, Emerald Scientific

Important Information for Our Customers

To Our Friends and Customers,

We recognize that these are unsettling times and we want you to know that the safety and health of our global community, including our valued customers and dedicated vendors, is of the utmost importance to us.

During this time, our commitment to you as a valued customer will continue to remain strong and steady. Our e-commerce lights will also remain on while our team across the country works virtually and practices strict social distancing.
 
We are in close contact with our vendors to ensure that customers like you are able to access all of our products and continue business as usual. I can say with confidence that we are well positioned in this regard due to the broad diversity among the vendors that we represent.
 
In an effort to help facilitate current strategic orders, we have stocked our warehouse with MilliporeSigma mobile phase solvents. In our experience, mobile phase solvents are an example of products that are imperative to operations and are often ordered with short lead time relative to operational needs. We are prepared to ship these products immediately and have also applied a discount.

Nothing is more important than your health and safety, and the need to protect those most vulnerable to the coronavirus. Please take care of yourselves and others.
 
Sincerely,

Ken Snoke
Founder, Emerald Scientific